PMID- 37029398
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230412
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Apr 7
TI  - Circulating levels of adropin and diabetes: a systematic review and meta-analysis 
      of observational studies.
PG  - 73
LID - 10.1186/s12902-023-01327-0 [doi]
LID - 73
AB  - OBJECTIVE: Adropin, a newly identified regulatory protein has garnered attention 
      given its potential role in metabolism regulation, especially glucose metabolism 
      and insulin resistance. However, studies on the association between adropin and 
      type 2 diabetes mellitus (T2DM) are equivocal. The aim of this study is to assess 
      the association between serum adropin levels and T2DM using a systematic review 
      and meta-analysis of observational studies. METHODS: PubMed, Scopus, ISI Web of 
      science, and Google Scholar were searched, up to August 2022, for studies that 
      reported the association between serum levels of adropin in adults with T2DM 
      compared to a control group without diabetes. A random-effect model was used to 
      compute the pooled weighted mean difference (WMD) with 95% confidence intervals 
      (CI). RESULTS: Meta-analysis of 15 studies (n = 2813 participants) revealed that 
      the serum adropin concentrations were significantly lower in patients with T2DM 
      compared with the control group (WMD= -0.60 ng/mL, 95% CI: -0.70 to -0.49; 
      I(2) = 99.5%). Subgroup analysis also found lower concentration of adropin in 
      patients with T2DM who were otherwise healthy compared to a control group (n = 9; 
      WMD=-0.04 ng/ml, 95% CI= -0.06 to -0.01, p = 0.002; I(2) = 96.4). CONCLUSIONS: 
      Our study showed adropin levels are lower in patients with diabetes compared to a 
      control group without diabetes. However, the limitations of observational studies 
      challenge the validity of the results, and further investigations are needed to 
      confirm the veracity of these findings and additionally explore possible 
      mechanisms.
CI  - (c) 2023. The Author(s).
FAU - Soltani, Sepideh
AU  - Soltani S
AD  - Yazd Cardiovascular Research Center, Non-communicable Diseases Research 
      Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
FAU - Beigrezaei, Sara
AU  - Beigrezaei S
AD  - Nutrition and Food Security Research Center, Shahid Sadoughi University of 
      Medical Sciences, Yazd, Iran.
AD  - Department of Nutrition, School of Public Health, Shahid Sadoughi University of 
      Medical Sciences, Yazd, Iran.
FAU - Malekahmadi, Mahsa
AU  - Malekahmadi M
AD  - Research Center for Gastroenterology and Liver Disease, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Clark, Cain C T
AU  - Clark CCT
AD  - Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, UK.
FAU - Abdollahi, Shima
AU  - Abdollahi S
AD  - Department of Nutrition, School of Public Health, North Khorasan University of 
      Medical Sciences, Bojnurd, Iran. sh.abd6864@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230407
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Enho protein, human)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Insulin Resistance
MH  - Observational Studies as Topic
MH  - *Intercellular Signaling Peptides and Proteins/blood
PMC - PMC10080945
OTO - NOTNLM
OT  - Adropin
OT  - Meta-analysis
OT  - Observational studies
OT  - Systematic review
OT  - Type 2 diabetes
COIS- The authors declare no competing interests.
EDAT- 2023/04/08 06:00
MHDA- 2023/04/11 06:42
PMCR- 2023/04/07
CRDT- 2023/04/07 23:36
PHST- 2023/01/13 00:00 [received]
PHST- 2023/03/21 00:00 [accepted]
PHST- 2023/04/11 06:42 [medline]
PHST- 2023/04/07 23:36 [entrez]
PHST- 2023/04/08 06:00 [pubmed]
PHST- 2023/04/07 00:00 [pmc-release]
AID - 10.1186/s12902-023-01327-0 [pii]
AID - 1327 [pii]
AID - 10.1186/s12902-023-01327-0 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2023 Apr 7;23(1):73. doi: 10.1186/s12902-023-01327-0.